Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma

Lilly

Status and phase: Completed; Phase 2

Conditions: Mantle-Cell Lymphoma

Treatments: Drug: enzastaurin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00088205

H6Q-MC-JCAO (Other Identifier)

8360

Details and patient eligibility

About

The purposes of this study are to determine the safety of oral enzastaurin and any side effects that might be associated with it and whether enzastaurin can help participants with mantle cell lymphoma.

Enrollment: 60 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Mantle cell lymphoma
• Previous treatment for mantle cell lymphoma
• Previously relapsed mantle cell lymphoma with no more than 4 chemotherapy regimens.
• Have discontinued all previous therapies for cancer, except corticosteroids up to 25 milligrams per day (mg/day)
• Adequate organ function

Exclusion criteria

• Inability to swallow tablets
• Must not have significant heart problems

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

60 participants in 1 patient group

A

Experimental group

Treatment:

Drug: enzastaurin